KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$117.4 million.

  • Recursion Pharmaceuticals' Cash from Operations fell 9815.96% to -$117.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$441.2 million, marking a year-over-year decrease of 3880.93%. This contributed to the annual value of -$359.2 million for FY2024, which is 2480.85% down from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Cash from Operations is -$117.4 million, which was down 9815.96% from -$76.4 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Cash from Operations high stood at $77.4 million for Q1 2022, and its period low was -$132.0 million during Q1 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' median Cash from Operations value was -$67.5 million (recorded in 2023), while the average stood at -$63.9 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 81337.92% in 2021, then skyrocketed by 35162.74% in 2022.
  • Recursion Pharmaceuticals' Cash from Operations (Quarter) stood at -$61.2 million in 2021, then rose by 26.83% to -$44.7 million in 2022, then plummeted by 65.54% to -$74.1 million in 2023, then tumbled by 55.82% to -$115.4 million in 2024, then decreased by 1.67% to -$117.4 million in 2025.
  • Its Cash from Operations was -$117.4 million in Q3 2025, compared to -$76.4 million in Q2 2025 and -$132.0 million in Q1 2025.